EU Panel Endorses Expanded Applications for Cancer Medications

Key Takeaways

• CHMP meeting highlights for 24-27 February 2025 record multiple oncology-related recommendations and variations.
• On 27 February 2025 CHMP adopted a positive opinion extending Enhertu to unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer after prior endocrine therapy.
• Keytruda has accumulated additional after-approval opinions,. This includes malignant pleural mesothelioma combinations and later SC-formulation use alignments.
• Positive CHMP opinions are not the same as final European Commission decisions until Commission implementing steps complete.

What did the February 2025 CHMP meeting signal for oncology?

EMA CHMP meeting highlights for 24-27 February 2025 summarize new recommendations, extensions of use, and other regulatory outcomes across the agenda.

Oncology teams should mine the highlights for both originator extensions and generics such as trabectedin that can alter tender dynamics.

Which Enhertu cancer expansion did CHMP back?

The CHMP summary of opinion for Enhertu dated 27 February 2025 recommends extending monotherapy to adults with unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer after at least one endocrine therapy who are not considered suitable for further endocrine therapy.

Existing HER2-positive breast, HER2-mutant NSCLC, and HER2-positive gastric or GEJ uses remain part of the evolving label text summarized in that opinion.

How is Keytruda expanding across cancer uses?

EMA variation pages document additional Keytruda changes,. This includes a May 21, 2026 positive opinion aligning subcutaneous Keytruda uses with several already authorized IV uses and adding a neoadjuvant/adjuvant MIBC combination opinion with enfortumab vedotin for cisplatin-ineligible adults.

Earlier after-approval opinions also addressed malignant pleural mesothelioma combinations, illustrating a continuous use-expansion cadence. Prefer a single October 2024 panel event.

What should investors track after a CHMP positive opinion?

• European Commission decision timing after CHMP opinion
• SmPC wording differences versus FDA labels
• Companion-diagnostic and marker constraints
• Tender and HTA implications in major EU5 markets

Commercial models should haircut revenue until Commission approval and national pricing steps are visible.

How do these EU cancer expansions change competitive maps?

ADC and PD-1 franchises gain new eligible pools, raising competitive pressure on endocrine-only sequences in HR-positive HER2-low disease and on before-and-after surgery bladder regimens.

Biosimilar and generic oncology entrants on the same CHMP agendas can compress older cytotoxics even as originator IO and ADC labels widen.

What remains unproven in EU panel narratives?

A single Medscape-dated October 17, 2024 claim that EMA voted to broaden several unnamed cancer drugs was not verified against the cited EMA primaries and is omitted.

CHMP positive opinions do not by themselves prove final EU marketing approval, reimbursement, or overall survival benefit beyond the evidence packages assessed for each variation.

How should EU oncology teams operationalize CHMP expansions?

Build use trackers that separate CHMP opinion dates from European Commission decision dates.

Align medical-info letters with the February 27, 2025 Enhertu HER2-low and HER2-ultralow wording once Commission text is final.

For Keytruda, note May 21, 2026 SC alignment opinions and the cisplatin-ineligible MIBC combination opinion with enfortumab vedotin.

Refresh tender models for cytotoxics when generics such as trabectedin appear on the same CHMP highlight notes.

Compare EMA SmPC marker rules with FDA labels before running one global forecast for each cancer use.

CHMP opinions come first. Commission decisions come next. Do not swap the two.

Enhertu gained a HER2-low and HER2-ultralow breast cancer opinion on 27 February 2025.

Keytruda keeps adding uses. Track each variation page on ema.europa.eu.

Tender teams should note new generics on the same meeting notes.

Use EMA PDFs for exact use text. Do not paraphrase from secondary news.

Mark each cancer use as opinion-only until the Commission decision posts.

Related NovaPharma coverage

• AstraZeneca Imfinzi bladder cancer approval
• Gilead Hepcludex FDA approval
• EU panel cancer drug expansions

Frequently Asked Questions

Primary Sources

1. EMA: CHMP meeting highlights Feb 2025
2. EMA: Enhertu CHMP summary of opinion
3. EMA: Keytruda variation positive opinion